Nonmyeloablative Allogeneic Transplantation With Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia With IDH Mutations: A Single Center Experience
| Autor: | Amy E. DeZern, Alexander J. Ambinder, Matthew D. Smith, Carol Ann Huff, Christian B. Gocke, Douglas E. Gladstone, Gabriel Ghiaur, William Dalton, Philip H. Imus, Mark J. Levis, Lukasz P. Gondek, Jonathan Webster, Ivana Gojo, Gabrielle T. Prince, Tania Jain, Margaret M. Showel, Ivan Borrello, Ravi Varadhan, Javier Bolaños-Meade, Hua-Ling Tsai, B. Douglas Smith, Nina Wagner-Johnston, Leo Luznik, Syed Abbas Ali, Richard Jones, Richard F. Ambinder, Ephraim J. Fuchs, Lode J. Swinnen |
|---|---|
| Rok vydání: | 2022 |
| Předmět: |
Cancer Research
medicine.medical_specialty Allogeneic transplantation Post transplant cyclophosphamide Single Center IDH2 Gastroenterology Article Internal medicine medicine Humans Transplantation Homologous Cumulative incidence Cyclophosphamide Univariate analysis business.industry Hematopoietic Stem Cell Transplantation Myeloid leukemia Hematology Transplant-Related Mortality Prognosis Isocitrate Dehydrogenase Leukemia Myeloid Acute Oncology Mutation business |
| Zdroj: | Clin Lymphoma Myeloma Leuk |
| ISSN: | 2152-2650 |
| DOI: | 10.1016/j.clml.2021.09.022 |
| Popis: | Introduction Mutations in the IDH1 or IDH2 genes are detected in approximately 20% of cases of acute myeloid leukemia (AML). Few studies have examined the impact of IDH mutations in AML on allogeneic bone marrow transplant (alloBMT) outcomes. Patients and methods In this single center study, alloBMT outcomes for 61 patients with IDH-mutated (mIDH) AML were compared to those for 146 patients with IDH-wildtype (wtIDH) AML. Results Patients with mIDH AML had a 2-year overall survival (OS) of 85% (95% CI 76%-95%), 2-year relapse free survival (RFS) of 71% (95% CI 59%-85%), 1-year cumulative incidence of relapse (CIR) of 14% (95% CI 5%-23%) and a 1-year cumulative incidence of transplant related mortality (CITRM) of 3% (95% CI 0%-8%). Patients with wtIDH had a 2-year OS of 61% (95% CI 53%-70%), 2-year RFS of 58% (95% CI 50%-67%), 1-year CIR of 27% (95% CI 20%-35%), and a 1-year CITRM of 9% (95% CI 5%-14%). In a univariate analysis cox-proportional hazard model, mIDH was associated with significantly better OS (HR 0.52, 95% CI 0.29-0.96) and a trend toward better RFS (HR 0.60, 95% CI 0.35-1.01). After controlling for donor age, diagnosis, and ELN risk category, mIDH was associated with a nonsignificantly improved OS (HR 0.54, 95% CI 0.29-1.01) and RFS (HR 0.67, 95% CI 0.39-1.15). Conclusion Among patients with mIDH AML, patients who received a peritransplant IDH inhibitor had improved OS (P = .03) compared to those who did not, but there was no detectable difference for RFS (P = .29). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect